Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy

Table 3 Cox proportional hazard analyses of overall survival

	Univariate		Multivariate
Variables	Hazard ratio (95% CI)	p-value	Hazard ratio (95% CI)	p-value
Age, ≥ 65 years	1.70 (1.11–2.59)	0.014	1.46 (0.94–2.27)	0.093
Sex, men	1.01 (0.65–1.61)	0.959
Smoking, ever-smoker	1.92 (1.20–3.22)	0.006	1.71 (1.04–2.91)	0.034
ECOG-PS*
0 vs. 1	0.67 (0.43–1.07)	0.096	0.76 (0.47–1.23)	0.253
0 vs. ≥ 2	0.21 (0.11–0.43)	< 0.001	0.28 (0.14–0.60)	0.002
1 vs. ≥ 2	0.31 (0.16–0.65)	0.003	0.37 (0.18–0.81)	0.014
Charlson comorbidity index*
0 vs. 1	0.93 (0.58–1.54)	0.762
0 vs. ≥ 2	1.26 (0.66–2.72)	0.506
1 vs. ≥ 2	1.36 (0.64–3.13)	0.432
GNRI, ≥ 92	0.39 (0.24–0.65)	< 0.001	0.51 (0.30–0.89)	0.018
Pathology, squamous cell (vs. non-squamous)	1.18 (0.73–1.84)	0.492
Stage, IIIb (vs. IV/ recurrent)	1.41 (0.76–2.42)	0.265
Platinum agents, cisplatin (vs. carboplatin)	0.71 (0.41–1.18)	0.195
Non-platinum agents*
Pemetrexed vs. taxane	0.84 (0.54–1.31)	0.437
Pemetrexed vs. others	1.13 (0.63–2.12)	0.688
Taxane vs. others	1.35 (0.76–2.53)	0.319
Treatment year, 2011–2020 (vs. 2000–2010)	1.15 (0.76–1.76)	0.519

CI confidence interval, ECOG-PS Eastern Cooperative Oncology Group performance status, GNRI Geriatric Nutritional Risk Index
*Hazard ratio was calculated for each pair of three categorical units

ISSN: 1471-2466